Last week, Allergan made an exciting announcement that the FDA has approved JUVÉDERM® VOLUX™ XC! This FDA approval is major news for the aesthetic medical industry because JUVÉDERM VOLUX XC is the first and only hyaluronic acid (HA) filler for improving jawline definition to be approved by the FDA.
Acara Partners is excited to learn about Allergan’s sixth product offering in the JUVÉDERM lineup of fillers and recognizes the FDA’s approval of JUVÉDERM VOLUX XC for improving jawline definition as a step forward for the aesthetic medical industry — medspa owners, injectors and patients alike.
In a press statement released by Allergan Aesthetics, an AbbVie company, Allergan states: “As the category leader, the JUVÉDERM® Collection of Fillers offers the broadest portfolio of specifically designed treatment options, and this latest approval of JUVÉDERM® VOLUX™ XC marks the sixth product offering in the lineup.”“‘The [FDA] approval of JUVÉDERM® VOLUX™ XC represents the largest leap in innovation for our U.S. HA portfolio since the introduction of JUVÉDERM® VOLUMA® XC, said Carrie Strom, President, Global Allergan Aesthetics and Senior Vice President, AbbVie. ‘JUVÉDERM® VOLUX™ XC is what our providers have been asking for to deliver the jaw-dropping results their patients are seeking.’”
Read the full Allergan Aesthetics Press Release: FDA Approves JUVÉDERM® VOLUX™ XC for Improvement of Jawline Definition
If you are interested in developing a medspa or adding aesthetic services to your existing medical practice, we’d love to hear from you. Contact us today to set up a complimentary consultation to discuss how to start your own medspa or increase sales and profits with Acara Partners.